These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3560348)

  • 1. Experimental treatment of prostatic cancer by intermittent hormonal therapy.
    Trachtenberg J
    J Urol; 1987 Apr; 137(4):785-8. PubMed ID: 3560348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal testosterone concentration for the treatment of prostatic cancer.
    Trachtenberg J
    J Urol; 1985 May; 133(5):888-90. PubMed ID: 3989932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats.
    Rosenberg CA; Hrushesky WJ; Langevin T; Kennedy BJ
    Oncology; 1985; 42(1):48-54. PubMed ID: 3969257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma.
    Sylvester PW; Ip MM
    Prostate; 1987; 10(1):57-67. PubMed ID: 3822918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma.
    Landström M; Tomić R; Damber JE
    Eur Urol; 1987; 13(3):203-6. PubMed ID: 2956111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiestrogens do not counteract the inhibitory effect of estradiol-17 beta on the growth of the Dunning R3327 prostatic adenocarcinoma.
    Landström M; Damber JE; Bergh A; Tomic R; Carlsson-Bostedt L; Stigbrand T
    Prostate; 1988; 12(4):287-98. PubMed ID: 3393491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology.
    Damber JE; Bergh A; Landström M; Tomić R
    J Urol; 1991 Jun; 145(6):1283-7. PubMed ID: 1827847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinate loss of growth regulatory factors following castration of rats carrying the Dunning R3327 G prostatic tumor.
    Rubenstein M; Shaw M; Targonski P; McKiel CF; Dubin A; Guinan PD
    Clin Physiol Biochem; 1992; 9(2):47-50. PubMed ID: 1284786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
    English HF; Heitjan DF; Lancaster S; Santen RJ
    Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma.
    Russo P; Liguori G; Heston WD; Huryk R; Yang CR; Fair WR; Whitmore WF; Herr HW
    Cancer Res; 1987 Nov; 47(22):5967-70. PubMed ID: 3664500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 6-methylene progesterone on growth, morphology, and blood flow of the Dunning R3327 prostatic adenocarcinoma.
    Damber JE; Bergh A; Daehlin L; Petrow V; Landström M
    Prostate; 1992; 20(3):187-97. PubMed ID: 1574466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen stimulated chemotherapy in the Dunning R-3327 prostatic adenocarcinoma.
    Grossman HB; Kleinert EL; Lesser ML; Herr HW; Whitmore WF
    Urol Res; 1981; 9(5):237-40. PubMed ID: 7303347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma.
    Daehlin L; Bergh A; Damber JE
    Urol Res; 1987; 15(3):169-72. PubMed ID: 3629752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
    Smolev JK; Heston WD; Scott WW; Coffey DS
    Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood flow in the Dunning R3327H rat prostatic adenocarcinoma; effects of oestradiol and testosterone.
    Daehlin L; Damber JE
    Urol Res; 1986; 14(2):113-7. PubMed ID: 3727214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82).
    van Steenbrugge GJ; Groen M; Romijn JC; Schröder FH
    J Urol; 1984 Apr; 131(4):812-7. PubMed ID: 6708205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
    Brändström A; Westin P; Bergh A; Cajander S; Damber JE
    Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion.
    Ip MM; Sylvester PW; Schenkel L
    Cancer Res; 1986 Apr; 46(4 Pt 1):1735-40. PubMed ID: 3948162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.